Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GLAXF) EBT (2016 - 2025)

Historic EBT for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $3.3 billion.

  • Gsk's EBT rose 388443.04% to $3.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 billion, marking a year-over-year increase of 4249.62%. This contributed to the annual value of $4.4 billion for FY2024, which is 4107.34% down from last year.
  • According to the latest figures from Q3 2025, Gsk's EBT is $3.3 billion, which was up 388443.04% from $2.5 billion recorded in Q2 2025.
  • In the past 5 years, Gsk's EBT ranged from a high of $4.8 billion in Q4 2023 and a low of $83.2 million during Q3 2024
  • Its 5-year average for EBT is $2.2 billion, with a median of $2.3 billion in 2023.
  • In the last 5 years, Gsk's EBT plummeted by 9633.46% in 2024 and then skyrocketed by 388443.04% in 2025.
  • Over the past 5 years, Gsk's EBT (Quarter) stood at $408.4 million in 2021, then skyrocketed by 758.63% to $3.5 billion in 2022, then skyrocketed by 37.81% to $4.8 billion in 2023, then decreased by 24.31% to $3.7 billion in 2024, then decreased by 9.42% to $3.3 billion in 2025.
  • Its last three reported values are $3.3 billion in Q3 2025, $2.5 billion for Q2 2025, and $2.7 billion during Q1 2025.